Table 1.

Clinical and laboratory findings at the time of renal biopsy in patients with C3 glomerulopathy

CategoryTotal (N=80)DDD (n=21)C3GN (n=59)P Value
Age (yr)
 Median21 (10–47)12 (8–20)26 (12–53)0.002
 <1632 (40)14 (68)18 (31)
Male sex41 (51)9 (43)32 (54)0.45
Race
 Caucasian73 (91)20 (95)53 (90)0.67
 Other7 (9)1 (5)6 (10)
Native biopsies (n=71; 16 DDD, 55 C3GN)0.07
 None2 (3)1 (5)1 (2)
 157 (71)11 (52)46 (78)
 212 (15)4 (19)8 (13)
Transplant biopsies (15 transplants; 7 DDD, 8 non-DDD)0.22
 None5 (33)1 (14)4 (50)
 15 (33)4 (57)1 (12.5)
 23 (20)2 (29)1 (12.5)
 ≥32 (14)02 (25)
Treatment
 Steroids33 (41)11 (52)22 (37)0.10
 Dialysis12 (15)5 (24)7 (12)0.12
 Other immunosuppressiona14 (17.5)4 (19)10 (17)0.37
 ACEI/ARB42 (52.5)12 (57)30 (51)0.24
 Antibiotics11 (14)2 (9.5)9 (15)0.39
 No specific treatment12 (15)1 (5)11 (19)0.15
Serum creatinine (mg/dl)
 Median1.1 (0.7–2.7)0.9 (0.7–2.3)1.4 (0.7–2.7)0.67
 >1.535 (44)6 (29)29 (50)
Proteinuria (g/24 h)
 Median3.0 (0.95–4.5)3.0 (1.5–3.5)3.0 (0.7–4.5)0.72
 <500 mg13 (16)2 (9)11 (19)
 500 mg to 3.5 g28 (35)9 (43)29 (32)
 >3.5 g35 (44)9 (43)26(44)
Hematuria (n=78 total; 21 DDD, 57 C3GN)0.54
 None10 (13)3 (14)7 (12)
 Microscopic53 (68)16 (76)37 (65)
 Frank15 (19)2 (10)13 (23)
Serum albumin (3.2–5.0 g/dl)
 Median (IQR)3.0 (2.4–3.5)3.0 (2.2–3.1)3.0 (2.6–3.5)0.23
 <3.033 (41)8 (38)25 (42)
Hypertension (n=77 total; 20 DDD, 57 C3GN)
 Normotensive43 (56)8 (40)35 (61)0.18
 Hypertensive34 (44)12 (60)22 (39)
C3 (n=69 total; 19 DDD, 50 C3GN) (0.65–1.65 g/L)
 Normal28 (41)2 (11)26 (52)0.003
 Low41 (59)17 (79)24 (48)
C4 (n=60 total; 13 DDD, 47 C3GN) (0.16–0.6 g/L)
 Normal46 (77)11 (85)35 (74)0.25
 Low14 (23)2 (1512 (36)
ASOT (n=35 total; 7 DDD, 28 C3GN)
 High19 (54)3 (43)16 (57)0.53
 Normal16 (46)4 (57)12 (43)
  • Data are presented as n (%) or the median (interquartile range). DDD, dense deposit disease; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASOT, antistreptolysin-O titer.

  • a Other immunosuppressions include cyclophosphamide, mycophenolate mofetil, tacrolimus, and plasma exchange used alone and in combination.